Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 24 08 2019
revised: 25 12 2019
accepted: 06 01 2020
pubmed: 25 1 2020
medline: 23 4 2020
entrez: 25 1 2020
Statut: ppublish

Résumé

Anthrax toxin receptor 1 (ANTXR1), a type I transmembrane protein, is one of the receptors that facilitates the entrance of anthrax toxin into cells. Previous studies have confirmed the pivotal role of ANTXR1 in progression and tumorigenesis of diverse cancer types. However, the biological function of ANTXR1 in gastric cancer (GC) is still unknown. The present study aimed to investigate the role of ANTXR1 in GC and illuminate the potential molecular mechanisms. Bioinformatics analysis found that ANTXR1 expression was significantly upregulated in GC tissue and its overexpression was associated with poor prognosis of GC patients. Moreover, we confirmed the upregulation of ANTXR1 in GC cell lines and GC tissue by quantitative PCR, western blot analysis, and immunohistochemical analysis. Additionally, high protein expression level of ANTXR1 was positively associated with several clinicopathological parameters in GC patients. In our study, a series of in vitro and in vivo assays were undertaken through strategies of loss/gain-of-function and rescue assays. Consequently, our results indicated that ANTXR1 induced proliferation, cell cycle progression, invasion and migration, and tumorigenicity and induced suppressed apoptosis in GC. Mechanistic investigation indicated that ANTXR1 exerted its promoting effects on GC through activation of the PI3K/AKT/mTOR signaling pathway. In conclusion, our findings suggested that ANTXR1 plays a crucial role in the development and progression of GC and could serve as a novel prognostic biomarker and potential therapeutic target for GC.

Identifiants

pubmed: 31977138
doi: 10.1111/cas.14326
pmc: PMC7156833
doi:

Substances chimiques

ANTXR1 protein, human 0
Biomarkers, Tumor 0
Microfilament Proteins 0
Receptors, Cell Surface 0
MTOR protein, human EC 2.7.1.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1132-1145

Subventions

Organisme : National Natural Science Foundation of China
ID : 81572819

Informations de copyright

© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Asian Pac J Cancer Prev. 2011;12(2):507-12
pubmed: 21545221
J Biol Chem. 2006 Aug 11;281(32):23227-36
pubmed: 16762926
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Anticancer Res. 2019 Apr;39(4):1689-1698
pubmed: 30952707
Pediatr Blood Cancer. 2015 May;62(5):743-50
pubmed: 25307519
Sci Rep. 2016 Mar 21;6:23419
pubmed: 26996335
Drug Resist Updat. 2002 Dec;5(6):234-48
pubmed: 12531180
Science. 2000 Aug 18;289(5482):1197-202
pubmed: 10947988
Crit Rev Oncol Hematol. 2009 Aug;71(2):127-64
pubmed: 19230702
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15583-8
pubmed: 20713715
J Cell Biochem. 2019 Apr;120(4):5010-5017
pubmed: 30260046
Virchows Arch. 2014 Jul;465(1):25-33
pubmed: 24844205
Clin Cancer Res. 2011 Feb 15;17(4):888-95
pubmed: 21304001
J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33
pubmed: 17971529
J Clin Invest. 2017 Aug 1;127(8):2957-2967
pubmed: 28650343
Anticancer Drugs. 2014 Nov;25(10):1129-40
pubmed: 25035961
Clin Exp Metastasis. 2004;21(1):31-7
pubmed: 15065600
J Cell Sci. 2001 Aug;114(Pt 15):2755-73
pubmed: 11683410
Int J Oncol. 2006 Nov;29(5):1311-7
pubmed: 17016666
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Res. 2013 Sep 15;73(18):5821-33
pubmed: 23832666
Cancer Res. 2004 Feb 1;64(3):817-20
pubmed: 14871805
Cancer Res. 2018 Jan 15;78(2):489-500
pubmed: 29183891
Cancer Sci. 2020 Apr;111(4):1132-1145
pubmed: 31977138
Onco Targets Ther. 2015 Sep 01;8:2427-33
pubmed: 26366097
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Cancer Treat Rev. 2019 Jan;72:45-55
pubmed: 30476750
Cancer Manag Res. 2018 Feb 07;10:239-248
pubmed: 29445300
Exp Cell Res. 2005 Apr 15;305(1):133-44
pubmed: 15777794
Mol Med Rep. 2018 Jan;17(1):911-917
pubmed: 29115620
Cancer Res. 2009 Aug 1;69(15):6021-6
pubmed: 19622764
Nature. 2001 Nov 8;414(6860):225-9
pubmed: 11700562
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Stem Cells Int. 2019 May 2;2019:1378639
pubmed: 31191663
Semin Cancer Biol. 2019 Dec;59:147-160
pubmed: 31128298
Br J Cancer. 2014 Oct 14;111(8):1657-62
pubmed: 25117815
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Oncolytic Virother. 2016 Sep 06;5:81-9
pubmed: 27660749
Methods Mol Biol. 2018;1655:335-350
pubmed: 28889395
Nat Commun. 2017 Jun 12;8:15861
pubmed: 28604699

Auteurs

Chen Cai (C)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Wei Dang (W)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Shilei Liu (S)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Ling Huang (L)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Yang Li (Y)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Guoqiang Li (G)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Siyuan Yan (S)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Chengkai Jiang (C)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Xiaoling Song (X)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Yunping Hu (Y)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Jun Gu (J)

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH